The FDA aims to leverage the expertise of qualified research institutions paired with drug sponsors to lessen the risk of ...

The FDA gathers Wednesday to hear what industry stakeholders and the public want included in the latest iteration of the ...

Safety and access were top of mind at Monday’s public hearing exploring the regulation of psychedelic therapies. "The ...

Analysts believe Cullinan Therapeutics and Taiho Oncology can overcome the safety risks as zipalertinib “sets [a] new bar” ...

In AD, BioVie has conducted Phase 2 and Phase 3 trials. Preliminary data from these trials suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a ...

GSK is consolidating its vaccine manufacturing operations to one site—located in Canada—amid what a spokesperson said is ...

Enrollment nearing completion in Phase 2 basket study of WAL0921; initial data from diabetic kidney disease cohorts to be presented in fourth quarter 2026 Data from Phase 1+ study of WAL0921 to be ...

Mr. Sylvain joined Dexcom in 2018 and has served as Executive Vice President and Chief Financial Officer since 2021. Throughout his tenure at Dexcom, Mr. Sylvain has built a strong finance leadership ...

Yarrow intends to use the net proceeds from this offering to fund research and development expenses for Yarrow’s pipeline and general corporate purposes, which may include working capital, capital ...

(Nasdaq: MIRM), a leading rare disease company, today announced that on September 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of ...

Bexlutry™ (lutetium Lu 177 dotatate injection) is indicated for the treatment of adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, ...

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of ...